YMAB - Yマブス・セラピュ―ティクス (Y-mAbs Therapeutics Inc.) Yマブス・セラピュ―ティクス

 YMABのチャート


 YMABの企業情報

symbol YMAB
会社名 Y-mAbs Therapeutics Inc (Yマブス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Y-mAbs Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing the therapeutic products for the treatment of cancer. Its product pipeline includes naxitamab and omburtamab. The Company’s lead antibody programs target GD2 and B7-H3. The Company develops naxitamab for the treatment of pediatric patients with relapsed or refractory (R/R) neuroblastoma (NB) and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system (CNS) leptomeningeal metastases (LM). The Company also creates humanized affinity matured bispecific antibodies. In addition the Company has two B7-H3 targeting product candidates omburtamab- diethylenetriamine pentaacetate (DTPA) and huB7-H3 which are in pre-clinical stage.   Yマブス・セラピュ―ティクスは米国のバイオ医薬品企業。米国内におけるがんの治療薬の新規開発と商品化に焦点をあて事業を行う。主に、再発性・難治性の高い小児がんである神経芽細胞腫や、線維形成性小円形細胞腫瘍および、びまん性橋グリオ―マの治療薬としてNaxitamabやOmburtamabの臨床試験を手掛ける。本社所在地はニューヨーク。   Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.
本社所在地 230 Park Avenue 33rd Floor New York NY 10169 USA
代表者氏名 Thomas Gad トーマス・ガード
代表者役職名 Chairman of the Board President Founder Head of Business Development and Strategy
電話番号 +1 212-847-9841
設立年月日 42095
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 29人
url www.ymabs.com
nasdaq_url https://www.nasdaq.com/symbol/ymab
adr_tso
EBITDA EBITDA(百万ドル) -30.84800
終値(lastsale) 24.015
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 701.48050
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 631.32850
当期純利益 当期純利益(百万ドル) -30.86800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Y-mAbs Therapeutics Inc revenues was not reported. Net loss increased from $6.1M to $17.8M. Higher net loss reflects Research and development - Balancing val increase from $4.5M to $13.8M (expense) General and administrative - Balancing v increase from $1.3M to $2.9M (expense) Stock-based Compensation in SGA increase of 66% to $367K (expense).

 YMABのテクニカル分析


 YMABのニュース

   Y-mAbs Therapeutics Inc (YMAB): Price Now Near $28.74; Daily Chart Shows Downtrend on 50 Day Basis  2021/08/26 15:21:03 ETF Daily News
This is a reversal of the price action on the previous hour, in which price moved up. The post Y-mAbs Therapeutics Inc (YMAB): Price Now Near $28.74; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .
   Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments  2021/08/05 20:01:00 Intrado Digital Media
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter of 2021.
   Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021  2021/07/29 20:05:00 Intrado Digital Media
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, August 6, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.
   Y-mAbs Announces NMPA Submission of BLA for DANYELZA (naxitamab-gqgk) in China  2021/07/06 12:37:00 Wallstreet:Online
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Y-mAbs, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that SciClone Pharmaceuticals (Holdings) Limited (SciClone Pharmaceuticals) has submitted the Biologics License
   Y-mAbs'' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA  2021/06/25 13:00:00 Benzinga
NEW YORK, June 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ: YMAB ) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Committee for Orphan Medicinal Products ("COMP") of the European Medicines Agency ("EMA") has recommended the granting of orphan medicinal product designation ("OMPD") in the European Union ("EU") for 177 Lu-omburtamab-DTPA for the treatment of medulloblastoma. The positive opinion from the EMA''s COMP has been sent to the European Commission ("EC"), which is expected to grant the orphan drug designation within 30 days. Obtaining OMPD for 177 Lu-omburtamab-DTPA is part of an overall plan to expand the Company''s European development programs and ultimately obtain orphan drug exclusivity to protect 177 Lu-omburtamab-DTPA for the treatment of medulloblastoma in the EU. Under the EMA''s Regulation (EC) No. 141/2000 an orphan medicinal product designation gives companies access to protocol assistance and guidance on preparing a dossier that will meet European regulatory requirements and thereby maximize the chance of approval at the time of marketing authorization.
   Y-mAbs Therapeutics Inc (YMAB): Price Now Near $28.74; Daily Chart Shows Downtrend on 50 Day Basis  2021/08/26 15:21:03 ETF Daily News
This is a reversal of the price action on the previous hour, in which price moved up. The post Y-mAbs Therapeutics Inc (YMAB): Price Now Near $28.74; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .
   Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments  2021/08/05 20:01:00 Intrado Digital Media
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter of 2021.
   Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021  2021/07/29 20:05:00 Intrado Digital Media
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended June 30, 2021 on Thursday, August 5, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, August 6, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.
   Y-mAbs Announces NMPA Submission of BLA for DANYELZA (naxitamab-gqgk) in China  2021/07/06 12:37:00 Wallstreet:Online
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Y-mAbs, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that SciClone Pharmaceuticals (Holdings) Limited (SciClone Pharmaceuticals) has submitted the Biologics License
   Y-mAbs'' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA  2021/06/25 13:00:00 Benzinga
NEW YORK, June 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ: YMAB ) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Committee for Orphan Medicinal Products ("COMP") of the European Medicines Agency ("EMA") has recommended the granting of orphan medicinal product designation ("OMPD") in the European Union ("EU") for 177 Lu-omburtamab-DTPA for the treatment of medulloblastoma. The positive opinion from the EMA''s COMP has been sent to the European Commission ("EC"), which is expected to grant the orphan drug designation within 30 days. Obtaining OMPD for 177 Lu-omburtamab-DTPA is part of an overall plan to expand the Company''s European development programs and ultimately obtain orphan drug exclusivity to protect 177 Lu-omburtamab-DTPA for the treatment of medulloblastoma in the EU. Under the EMA''s Regulation (EC) No. 141/2000 an orphan medicinal product designation gives companies access to protocol assistance and guidance on preparing a dossier that will meet European regulatory requirements and thereby maximize the chance of approval at the time of marketing authorization.
   H.C. Wainwright Stick to Their Buy Rating for Y-Mabs Therapeutics By Investing.com  2021/04/21 10:25:12 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Y-Mabs Therapeutics
   Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer  2021/04/20 16:18:46 Benzinga
Y-mAbs Therapeutics Inc (NASDAQ: YMAB ) recently concluded a Type B meeting with the FDA regarding omburtamab in CNS/leptomeningeal metastasis from neuroblastoma. The company received requests from the agency for additional data concerning the granularity of data from identified historical control groups. Omburtamab is an investigational … Full story available on Benzinga.com
   Y-mAbs Therapeutics Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/02/24 20:59:00 Stock Market Daily
Y-mAbs Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Y-mAbs Therapeutics Raises $100M Via Equity To Fund Commercial Rollout Of Neuroblastoma Med - Stocks News Feed  2021/02/18 10:20:37 Stocks News Feed
Y-mAbs Therapeutics Inc (NASDAQ: YMAB) priced its public offering of 2.4 million common shares at $41 per share, for gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 365,853 shares. The offering is expected to close by February 22. J.P. Morgan, Morgan Stanley, and BofA Securities are acting as the joint book-running… Read More »Y-mAbs Therapeutics Raises $100M Via Equity To Fund Commercial Rollout Of Neuroblastoma Med
   Y-mAbs Announces Sale of Priority Review Voucher | MarketScreener  2020/12/28 14:00:01 MarketScreener
NEW YORK, Dec. 28, 2020 -- Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic… | December 28, 2020

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 Yマブス・セラピュ―ティクス YMAB Y-mAbs Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)